Biogen Inc. has synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory disorders, liver diseases, pain and neurodegeneration, among others.
Presage Biosciences Inc. has announced that the FDA has issued a study may proceed notification for testing a pre-GMP drug candidate with the company’s Comparative In Vivo Oncology (CIVO) platform. Owned by Pure Biologics, the drug candidate, PBA-0405, is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
E-Therapeutics plc has offered a pipeline update, following the nomination of novel target genes, which have yielded promising results in preclinical studies.
SUMOylation is a post-translational modification implicated in DNA damage repair that has been linked to the lack of efficacy of some therapies commonly used for the treatment of leukemia.
Cellectar Biosciences Inc. has released promising preclinical data for its proprietary novel α-emitting phospholipid radiotherapeutic conjugate, CLR-121225 (225Ac-CLR-121225), an actinium-labeled phospholipid ether, in refractory pancreatic cancer mouse xenograft models.
Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.
Overexpression of the enhancer of zeste homolog 2 (EZH2) has been found in multiple cancer types, such as myeloma, lymphoma, prostate, breast, lung or kidney cancer.
RSS
